Vitality Watch

Dossier clinicaltrials trial early 10-sep-2026
Small or early-phase human trial or pilot study

Effect of Pentadecanoic Acid Supplementation on Red Blood Cell Health and Biological Aging in Healthy Older Adults

Key claim: A Phase II randomized trial will test whether 200–300 mg daily pentadecanoic acid (C15:0) for 12 weeks improves red blood cell health (RDW-CV) and biological-age-related biomarkers versus placebo in healthy adults aged 55+.

Abstract

This Phase II randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effects of pentadecanoic acid (C15:0) supplementation on red blood cell (RBC) health and predicted biological age in healthy adults aged 55 years and older. A total of 93 participants will be randomized to receive 200 mg of C15:0, 300 mg of C15:0, or placebo daily for approximately 12 weeks. The primary objective is to assess the effect of C15:0 on red blood cell distribution width (RDW-CV), a marker of RBC health, compared with placebo. Secondary outcomes include measures of inflammation, hematologic and iron metabolism markers, circulating C15:0 levels, biological age-related biomarkers, sleep quality, fatigue, energy, and health-related quality of life. Safety and tolerability will also be evaluated throughout the study.

Why this matters

C15:0 has spread through consumer channels (Fatty15 branding, podcast circuit) largely on mechanism and observational signals; a registered Phase II RCT with defined biological-age endpoints is the first formal test in the population being marketed to. The trend has been running ahead of the evidence — this protocol is the first move toward closing that gap, though a readout is still pending.

Source

Link

Briefing card

Effect of Pentadecanoic Acid Supplementation on Red Blood Cell Health and Biological Aging in Healthy Older Adults
Stage: trial early · clinicaltrials · 10-sep-2026

If you take C15:0 supplements for longevity, controlled human evidence on RBC and biological-age markers is still pending — this trial is the test, not the answer.

A Phase II randomized trial will test whether 200–300 mg daily pentadecanoic acid (C15:0) for 12 weeks improves red blood cell health (RDW-CV) and biological-age-related biomarkers versus placebo in healthy adults aged 55+.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07812792

build build 880 · 2bcef25 · 2026-11-18